Drug Profile
IM19 chimeric antigen receptor T cell therapy - Beijing Immunochina Medical Science and Technology
Alternative Names: IM19 CAR-T cells; IM19-CAR-T-Cells-Beijing-Immunochina-Medical-Science-and-Technology; IM19CAR-T; IM19CAR-T-Beijing-Immunochina-Medical-Science-and-TechnologyLatest Information Update: 30 Jan 2024
Price :
$50
*
At a glance
- Originator Beijing Immunochina Medical Science and Technology
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Diffuse large B cell lymphoma; Leukaemia
- Phase I/II Mantle-cell lymphoma; Non-Hodgkin's lymphoma
- Phase I Precursor B-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 09 Dec 2023 Phase-I/II clinical trials in Mantle-cell lymphoma (Second-line therapy or greater) (Parenteral) before December 2023 (NCT05155215)
- 09 Dec 2023 Efficacy data from a phase I/II trial in Mantle cell lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 01 Dec 2023 Phase-I clinical trials in Mantle-cell lymphoma in China (Parenteral) prior to December 2023 (Beijing Immunochina Medical Science and Technology pipeline, December 2023)